New York, May 31, 2026, 16:05 (EDT)
SciSparc Ltd. is set to open Monday with shares well above last week, after a deal report made the Nasdaq-traded drug maker one of last week’s most volatile microcap stocks. U.S. markets are open following the Memorial Day break; Nasdaq’s 2026 calendar put May 25 as a holiday.
SciSparc shares finished Friday at $9.81, dropping 7.0% for the session. That left the stock up about 130% from its May 22 finish at $4.27. SciSparc didn’t get there in a straight line. Shares spiked to $10.55 at the close on May 28 with 35.7 million changing hands, then volume fell to 824,800 traded on Friday, Yahoo Finance data show.
SciSparc’s new Form 6-K puts the focus on timing. The company said NeuroThera Labs and selling shareholders extended the deadline for closing the NeuroThera-CliniQuantum deal to June 1. They’re still working on required steps like an Israeli tax decision and getting final TSX Venture Exchange sign-off.
SciSparc said its unit NeuroThera got conditional approval from the TSX Venture Exchange to buy roughly 54% of CliniQuantum. The exchange has accepted the transaction, but it still has to meet some requirements before it’s done. This isn’t final approval, SciSparc said.
NeuroThera said it will buy 56,375 ordinary shares of CliniQuantum, paying with 56.6 million NeuroThera common shares. The NeuroThera stock is valued around $9.46 million, according to the company’s 20-day volume-weighted average price. The volume-weighted price means trades with heavier volume have more influence on the average.
CliniQuantum, a private firm in Israel, is building a platform that applies quantum simulation and quantum Monte Carlo techniques to clinical-trial data. The company’s basic pitch: better modeling might pinpoint which patients could benefit most from an experimental drug.
SciSparc’s stake in NeuroThera is affected by the deal, too. A March filing showed SciSparc’s ownership was set to drop to about 43.86% from around 75% after the transaction closes. CliniQuantum sellers could get up to $2.5 million more in earn-out payments if milestones happen. An earn-out means extra pay when specific goals are reached.
Big U.S. indexes finished at record highs Friday. The Dow, S&P 500 and Nasdaq advanced. The Russell 2000 dropped. That gap can hurt names like SciSparc, since microcap rallies often fade when investors pull back on risk.
SciSparc is a clinical-stage pharma group in Tel Aviv working on cannabinoid tech for central nervous system disorders. The company lists programs like SCI-110, which targets Tourette syndrome and Alzheimer’s disease with agitation, and SCI-210, aimed at autism spectrum disorder and status epilepticus. THC, found in cannabis, is psychoactive. CBD, another compound, is not.
Peer group is thin. Clearmind Medicine, a small biotech tied to NeuroThera in patent filings, said Friday it moved forward on a Japanese patent for a depression treatment. Jazz Pharmaceuticals’ Epidiolex is still the main prescription CBD name. SciSparc, much earlier stage than Jazz, saw shares move this week on a transaction development, not drug news or trial results.
There’s clear risk. NeuroThera flagged that closing the CliniQuantum acquisition still depends on conditions like TSXV approval and an Israeli tax ruling, and said there’s no guarantee the deal will go ahead as laid out or even close at all. The company pointed out CliniQuantum is still early and hasn’t posted any revenue so far.
SciSparc is also under balance-sheet pressure. In its 2025 annual report, the company said it had $4.6 million in cash and cash equivalents, including restricted deposits, as of Dec. 31. That amount isn’t enough to fund planned operations for at least a year after the filing date. The filing pointed to “substantial doubt” about SciSparc’s ability to keep operating as a going concern, with both auditors and management flagging uncertainty over keeping the business running without more cash. SEC
Listing pressure weighs as well. SciSparc on May 11 said Nasdaq had deemed it conditionally compliant with a stockholders’ equity rule. But if the company can’t show ongoing compliance in its next periodic report, it could again face a delisting threat. Stockholders’ equity means what’s left for owners after subtracting liabilities from assets.
In the coming week, traders are focused on a possible June 1 update on CliniQuantum and whether Friday’s low volume means demand is cooling. They’re also watching if the stock can keep its gains without a fresh filing. For now, it’s more about a deadline and a thinly traded stock than a completed acquisition, with the market still chasing catalysts.
